Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK

Nonalcoholic steatohepatitis (NASH) is recognized by hepatic lipid accumulation, inflammation, and fibrosis. No studies have evaluated the prolonged‐release pirfenidone (PR‐PFD) properties on NASH features. The aim of this study is to evaluate how PR‐PFD performs on metabolic functions, and provide...

Full description

Bibliographic Details
Main Authors: Ana Sandoval‐Rodriguez, Hugo Christian Monroy‐Ramirez, Alejandra Meza‐Rios, Jesus Garcia‐Bañuelos, Jose Vera‐Cruz, Jorge Gutiérrez‐Cuevas, Jorge Silva‐Gomez, Bart Staels, Jose Dominguez‐Rosales, Marina Galicia‐Moreno, Monica Vazquez‐Del Mercado, Jose Navarro‐Partida, Arturo Santos‐Garcia, Juan Armendariz‐Borunda
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2020-03-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1474

Internet

https://doi.org/10.1002/hep4.1474

Similar Items